A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer

A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancerA balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer, Published online: 05 October 2018; doi:10.1038/s41571-018-0108-xA minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research